|drug369||BIOMARKERS IN THE LONG TERM IMPACT OF CORONAVIRUS INFECTION IN THE CARDIORRESPIRATORY SYSTEM Wiki||0.71|
|drug2010||Mindfulness Based Intervention Wiki||0.50|
|D000077062||Burnout, Psychological NIH||0.16|
|D014777||Virus Diseases NIH||0.08|
|D003141||Communicable Diseases NIH||0.05|
There are 2 clinical trials
Phase IIa clinical trial in which 75 non-ICU hospital inpatients will be randomized 2:1 to 7 days of an oral formulation of cyclosporine, Neoral (2.5mg/kg PO BID) + standard of care (SOC) or no Neoral + SOC. The primary endpoint is disease severity based on the World Health Organization (WHO) COVID Ordinal Outcomes Scale, on day 14. Secondary endpoints include safety and changes in serum inflammatory markers.
Description: WHO COVID-19 clinical severity scale. Score 0-9. 0=Uninfected, 8=Death.Measure: WHO COVID-19 clinical severity scale Time: Through study completion, an average of 1 month.
This study will evaluate the efficacy of oral Foipan® (camostat mesilate) compared with the current standard of care in reducing the duration of viral shedding of SARS-CoV-2 virus in patients with mild-moderate COVID-19 disease. Patients will attend 4 study visits over a period of up to 28 days.
Description: This outcome is defined as the time in days from randomization to the first of two consecutive negative RT-PCR results of self-collected nasal swabs.Measure: Time until cessation of shedding of SARS-CoV-2 virus Time: Up to 28 days
Description: Number of symptomatic patients with clinical worsening, defined as the development of respiratory distress or symptoms that require hospitalization.Measure: Clinical worsening of COVID-19 disease in symptomatic patients Time: Up to 28 days
Description: Number of patients that develop antibodies to SARS-CoV-2.Measure: Development of antibodies to SARS-CoV-2 Time: Up to 28 days
Description: This outcome is defined as absence of moderate or severe symptoms for at least 24 hours for those reporting moderate or severe symptoms at baselineMeasure: Time until resolution of symptoms Time: Up to 28 days
Description: Progression of respiratory symptoms defined as a two-level increase of a symptom on the Daily Symptom Status Questionnaire within a 24 hour period, or a one-level increase of a symptom on the Daily Symptom Status Questionnaire observed/sustained for a consecutive 48 hour period.Measure: Time until progression of symptoms Time: Up to 28 days
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports